TD Cowen Reaffirms Buy Rating for Twist Bioscience (NASDAQ:TWST)

TD Cowen reaffirmed their buy rating on shares of Twist Bioscience (NASDAQ:TWST) in a research report report published on Tuesday,Benzinga reports. They currently have a $58.00 target price on the stock.

A number of other brokerages have also recently weighed in on TWST. Evercore ISI boosted their price objective on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Robert W. Baird boosted their price objective on Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research note on Tuesday, November 19th. Scotiabank boosted their price objective on Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research note on Tuesday, November 19th. Barclays reduced their price objective on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research note on Tuesday, November 19th. Finally, Leerink Partners boosted their price objective on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Twist Bioscience currently has a consensus rating of “Moderate Buy” and an average price target of $51.00.

Twist Bioscience Stock Down 0.1 %

TWST stock opened at $46.34 on Tuesday. Twist Bioscience has a fifty-two week low of $23.07 and a fifty-two week high of $60.90. The business has a 50 day moving average price of $43.78 and a 200 day moving average price of $46.18. The stock has a market cap of $2.75 billion, a price-to-earnings ratio of -13.02 and a beta of 1.78.

Insider Buying and Selling

In related news, SVP Paula Green sold 3,310 shares of the company’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $43.21, for a total transaction of $143,025.10. Following the transaction, the senior vice president now owns 84,585 shares of the company’s stock, valued at $3,654,917.85. This represents a 3.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Robert F. Werner sold 1,448 shares of the company’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total value of $64,580.80. Following the transaction, the chief accounting officer now directly owns 45,620 shares in the company, valued at $2,034,652. This represents a 3.08 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 98,118 shares of company stock valued at $4,391,151 over the last quarter. Company insiders own 3.92% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Wilmington Savings Fund Society FSB acquired a new position in Twist Bioscience during the third quarter worth $34,000. Signaturefd LLC grew its holdings in Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after purchasing an additional 306 shares during the last quarter. EdgeRock Capital LLC acquired a new stake in Twist Bioscience in the second quarter valued at $43,000. Blue Trust Inc. grew its holdings in Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after purchasing an additional 1,136 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale acquired a new stake in Twist Bioscience in the second quarter valued at $61,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.